Common side effects and risk management methods of Sunitinib (Sutent)

Sunitinib (Sunitinib) is an oral small molecule multi-target tyrosine kinase inhibitor (TKI), which mainly inhibits VEGFR Receptor kinases such as , PDGFR, KIT and FLT3 block tumor angiogenesis and cell proliferation signals, thereby inhibiting tumor growth. Sunitinib is widely used in the treatment of renal clear cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and other advanced solid tumors. Despite its remarkable efficacy, sunitinib is also accompanied by a variety of side effects in clinical application. Its mechanism is related to targeting and endothelial inhibition. Patients need to fully understand and respond in a timely manner to ensure efficacy and safety.

First, hematological side effects are common adverse reactions of sunitinib, including neutropenia, thrombocytopenia, and anemia. Neutropenia may increase the risk of infection. Patients should regularly monitor blood routine during treatment. If a significant decrease in white blood cells is found, the drug needs to be temporarily stopped or the dose adjusted under the guidance of a doctor, and anti-infection or growth factor support treatment should be given as needed. Thrombocytopenia and anemia may also lead to bleeding and fatigue. Supportive treatment, such as blood transfusions or erythropoietin, can be used if necessary, while medications that increase the risk of bleeding can be avoided.

Second, gastrointestinal adverse reactions are very common with sunitinib treatment, including nausea, vomiting, diarrhea, decreased appetite, and oral inflammation. Mild to moderate patients can relieve symptoms through symptomatic treatment such as dietary adjustments, anti-nausea drugs, oral care, and rehydration. In patients with severe diarrhea or persistent vomiting, short-term discontinuation or dose reduction should be considered while paying attention to electrolyte balance and risk of dehydration. Uncontrolled long-term gastrointestinal reactions may affect drug compliance, so patients need to closely observe physical reactions in the early stages of medication.

Thirdly, skin and mucous membrane side effects are also relatively common, such as hand and foot skin reactions (palm and plantar redness, swelling, pain), rash, hair loss, and dry skin. This type of reaction is mainly related to VEGFRinhibition. Mild to moderate skin reactions can be relieved with topical moisturizers, hand and foot creams, or anti-itch medications; in severe cases, the dose may need to be adjusted or the medication temporarily discontinued to prevent skin ulcers or infection. Patients should pay attention to skin care during treatment and avoid excessive friction, hot water soaking, or irritating cosmetics to reduce the risk of side effects.

In addition, cardiovascular and metabolic abnormalities are also common adverse reactions of sunitinib, including hypertension, hypocardia, QT interval prolongation, thyroid dysfunction, etc. Patients should have their cardiac function assessed and their blood pressure and electrocardiogram monitored before treatment. Antihypertensive drugs can be used when high blood pressure occurs; if the cardiac function decreases significantly or the QT interval is prolonged, the drug should be stopped or the dose should be adjusted in time, and the treatment should be handled under the guidance of a cardiologist. Abnormal thyroid function can be monitored by monitoring thyroid hormone levels and providing appropriate drug intervention.

Sunitinib may also cause side effects such as fatigue, weakness, bleeding tendencies, abnormal liver function, and abnormal renal function. Patients should regularly review their liver and kidney functions during treatment, and adjust the dosage according to clinical conditions. When serious adverse reactions occur, doctors will take measures such as dose reduction, temporary discontinuation or permanent discontinuation of medication according to CTCAE grading guidelines to ensure safety.

In clinical management, individualized medication and early intervention are key to reducing the risk of side effects. Patients should inform their doctor in detail about their past medical history and concomitant medications before taking medication, and hematological indicators, liver and kidney function, heart function and blood pressure should be reviewed regularly during treatment. Mild and moderate side effects can be alleviated through symptomatic treatment and lifestyle adjustments; for severe side effects or side effects involving vital organs, the dose needs to be adjusted immediately or the drug discontinued, and the treatment must be carried out under the guidance of a doctor.

In general, sunitinib has clear efficacy in the treatment of renal clear cell carcinoma, GIST and other tumors, but it is accompanied by various side effects such as hematological abnormalities, gastrointestinal reactions, skin toxicity and cardiovascular events. Through standardized monitoring, individualized dose adjustment and symptomatic treatment, most side effects can be effectively managed. Patients should maintain close communication with their doctors during medication and report discomfort symptoms in a timely manner to ensure treatment safety, improve compliance, and achieve the best treatment effect.

Reference materials:https://www.drugs.com/